Access, Adherence and Patient-Reported Outcomes of Hydroxyurea Therapy in Sickle Cell Disease: A Cross-Sectional Study from Nigeria
Kaladada Ibitrokoemi Korubo, Emmanuel Wobo & Uchechukwu Prince Okite · International Blood Research & Reviews · 2026
Background: Hydroxyurea is the most accessible disease-modifying therapy for sickle cell disease (SCD), but in many low- and middle-income countries its real-world benefit is constrained by gaps in awareness, uptake, continuity, and adherence. We analyzed the full hydroxyurea pat...
Open access
Research Article
10.9734/ibrr/2026/v17i2382